Messing with cancer therapy: how the melanoma phenotype predicts checkpoint inhibitor response

• Svenja Meierjohann,
• Corine Bertolotto

Affiliations

Svenja Meierjohann

Institute of Pathology, University of Würzburg

Corine Bertolotto

University Côte d’Azur, Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, Centre Méditerranéen de Médecine Moléculaire